Foghorn Therapeutics
Foghorn is pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression. These precision therapeutic candidates target disease dependencies within the chromatin regulatory system, which means they change how genes turn on and off. Our therapies have the potential to be the next wave of medicines for cancer and other diseases.
Basic Information
- Category: Oncology
- Founded: 2016
- Headquarters: Cambridge, MA
- Website: foghorntx.com
Documented Facts
- Email: info@foghorntx.com (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: DE (No linked source recorded for this statement.)
- Stock ticker: FHTX (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Foghorn Therapeutics — Official Site (official)
- Foghorn Therapeutics on linkedin (social)
- Foghorn Therapeutics Inc. — SEC EDGAR (reference)
Citation Guidance
Explore Oncology profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Foghorn Therapeutics.
- Canonical profile: https://brandsource.ai/brands/foghorn-therapeutics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/foghorn-therapeutics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/foghorn-therapeutics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T20:51:29.117Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Foghorn is pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression. These precision therapeutic candidates target disease dependencies within the chromatin regulatory system, which means they change how genes turn on and off. Our therapies have the potential to be the next wave of medicines for cancer and other diseases.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.